Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Relief as Apex Indian court seeks details on trial safeguards

This article was originally published in Scrip

Executive Summary

In what perhaps will come as a significant relief for industry, the Supreme Court order in a case concerning clinical trials in India appears less harsh than originally made out to be, with the apex court only seeking certain details on how the current regime safeguards trial participants with reference to the clearances granted for 162 proposals by the Drugs Controller General of India (DCGI).





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts